QQ客服 官方微博 反馈留言

	Elevated levels of pre-treatment lactate dehydrogenase are an unfavorable predictor factor in patients with EML4-ALK rearrangement non-small cell lung cancer treated with crizotinib
	Liang Hongge; Ma Di; Xu Yan; Zhao Jing; Chen Minjiang; Liu Xiaoyan; Zhong Wei; Li Junling; Wang Mengzhao
	2019
卷号	11页码:8191-8200
关键词	crizotinib echinoderm microtubule-associated protein-like 4–anaplastic lymphoma kinase lactate dehydrogenase non-small cell lung cancer progression-free survival
ISSN号	1179-1322
DOI	10.2147/CMAR.S213572
URL标识	查看原文
收录类别	PUBMED
内容类型	期刊论文
URI标识	http://www.corc.org.cn/handle/1471x/6335768
专题	中国医学科学院 北京协和医学院
推荐引用方式 GB/T 7714	Liang Hongge,Ma Di,Xu Yan,et al. Elevated levels of pre-treatment lactate dehydrogenase are an unfavorable predictor factor in patients with EML4-ALK rearrangement non-small cell lung cancer treated with crizotinib[J],2019,11:8191-8200.
APA	Liang Hongge.,Ma Di.,Xu Yan.,Zhao Jing.,Chen Minjiang.,...&Wang Mengzhao.(2019).Elevated levels of pre-treatment lactate dehydrogenase are an unfavorable predictor factor in patients with EML4-ALK rearrangement non-small cell lung cancer treated with crizotinib.,11,8191-8200.
MLA	Liang Hongge,et al."Elevated levels of pre-treatment lactate dehydrogenase are an unfavorable predictor factor in patients with EML4-ALK rearrangement non-small cell lung cancer treated with crizotinib".11(2019):8191-8200.

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。